Wall Street Analysts Say Valeant's Stock Collapse Is a Buying Opportunity
Wall Street stock analysts are so far not convinced by the critical report.
This article is for subscribers only.
Shares of Valeant took quite the beating yesterday after Citron Research accused the company of an Enron-like accounting strategy. At one point, the stock fell as much as 40 percent before Valeant posted a rebuttal calling the short seller’s allegations “erroneous.”
Analysts on Wall Street had some work to do following this report, and this morning we're getting updated research from a number of firms. So far it seems the majority of the Street is calling this a chance to get the stock at a discount.